Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with very ...
Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...
张子豪，B站UP主“同济子豪兄”，24万粉丝，视频累计播放量超过1300万，四次登上热搜。 长期从事人工智能、深度学习、计算机视觉的科普教育工作。微软人工智能最有价值专家（MVP）、华为云人工智能HCDE云享专家、中国图象图形学学会-科普与教育工作委员会 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈